Scarica l'app Stockscreener
3.43
0.58%
-0.02
Dopo l'orario di chiusura:
3.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.45
Aprire:
$3.335
Volume 24 ore:
7.75M
Relative Volume:
0.53
Capitalizzazione di mercato:
$1.41B
Reddito:
$263.44M
Utile/perdita netta:
$-390.98M
Rapporto P/E:
-3.0598
EPS:
-1.121
Flusso di cassa netto:
$-336.24M
1 W Prestazione:
-7.05%
1M Prestazione:
-9.50%
6M Prestazione:
+52.44%
1 anno Prestazione:
-3.11%
Intervallo 1D:
$3.32
$3.505
Intervallo di 1 settimana:
$3.26
$3.715
Portata 52W:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.43 | 1.41B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm
Why is Iovance Biotherapeutics Inc stock going up2026 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices - Sahm
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More - GlobeNewswire Inc.
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Market Outlook: Is Iovance Biotherapeutics Inc a stock for growth or value investors2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Volume Recap: Is Iovance Biotherapeutics Inc still a buy after recent gains2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
IOVA | Iovance Biotherapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics (MIL:1IOVA) NonCurrent Deferred Rev - GuruFocus
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Iovance downgraded to Neutral at UBS related to Amtagvi concerns - MSN
Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript - GuruFocus
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial - MarketBeat
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Advanced Cell-based Therapy Booming the Success for Healthcare Sector - Sahm
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - sahmcapital.com
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - simplywall.st
Iovance Biotherapeutics Announces Upcoming Board Member Retirement - The Globe and Mail
Iovance Biotherapeutics board member Wendy Yarno to retire after current term - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 20 March - Investing.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting - Stock Titan
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeu - The National Law Review
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (IOVA) Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational TrialWhat's Changed - Sahm
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics (IOVA) announces positive early data for lifileucel TIL therapy in advanced sarcomas - MSN
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
39,059 |
0 |
257,590 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
142,394 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 02 '26 |
Option Exercise |
0.00 |
52,087 |
0 |
516,609 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,307 |
0 |
118,051 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
221,329 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,697 |
0 |
124,353 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 24 '26 |
Option Exercise |
0.00 |
120,000 |
0 |
173,546 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
39,996 |
0 |
69,996 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,906 |
0 |
113,640 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):